Open AccessCurrent Understanding and Potential Immunotherapy for HIV‐Associated Squamous Cell Carcinoma of the Anus (SCCA)
Author(s) -
MarinMuller Christian,
Li Min,
Chen Changyi,
Yao Qizhi
Publication year - 2009
Publication title -
world journal of surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.115
H-Index - 148
eISSN - 1432-2323
pISSN - 0364-2313
DOI - 10.1007/s00268-008-9835-y
Subject(s) - medicine , immunotherapy , anal cancer , anal carcinoma , disease , population , anus , hpv vaccines , immunology , oncology , cancer , hpv infection , cervical cancer , immune system , surgery , environmental health
Squamous cell carcinoma of the anus (SCCA) is a rare disease in the average population but is an increasing concern among immunocompromised individuals, such as the HIV‐seropositive. Coinfection with human papillomavirus (HPV) in this population is common. HPV infection is difficult to clear with a compromised immune system, which results in a greater risk of tumor development and a more aggressive progression of the disease. The recent approval of a prophylactic HPV vaccine for cervical cancer has sparked an interest in a search for improved immunotherapeutic multimodality therapies to combat anogenital tumors associated with the virus. In this review, we discuss the known mechanisms of action of HIV‐associated SCCA, examine the current treatments for the disease, and focus on the potential of an immunotherapeutic vaccine approach for both prophylactic and therapeutic application.